Virpax Pharmaceuticals effects 1-for-25 reverse stock split effective March 21, 2025

Virpax Pharmaceuticals, Inc.

Reverse split ratio set at 1-for-25, effective 12:01 a.m. ET on March 21, 2025.
Outstanding shares reduced from 31,062,581 to 1,242,504.
Trading symbol VRPX unchanged; new CUSIP 928251305.
Board approved final ratio on March 5, 2025, following stockholder authorization on January 15, 2025.
Equity awards and warrants proportionally adjusted for the split.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Virpax Pharmaceuticals, Inc.: Filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2025-03-21).

Change: charter amendment
Effective: 2025-03-21

Exact text from the filing

On March 12, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) to effect a 1-for-25 reverse stock split

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001731122-25-000427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.